| Resolor (prucalopride) / J&J, Takeda |
NCT00576511: Effect of Prucalopride in Patients With Severe Chronic Idiopathic Constipation |
|
|
| Completed | 2 | 53 | Europe | prucalopride, Resolor, placebo | Movetis | Chronic Constipation | 02/96 | 02/96 | | |
NCT00617513: Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation |
|
|
| Completed | 2 | 174 | Europe | Prucalopride, Resolor, Placebo | Movetis | Constipation | 03/96 | 03/96 | | |
NCT00631813: Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation |
|
|
| Completed | 2 | 253 | Europe | Prucalopride, Resolor, Placebo | Movetis | Constipation | 04/97 | 04/97 | | |
NCT00596596: Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation |
|
|
| Completed | 2 | 313 | US | prucalopride, Resolor, 2 mg prucalopride, 4 mg prucalopride, Placebo | Movetis | Constipation | 06/97 | 06/97 | | |
NCT00575614: Prucalopride in Patients With Chronic Idiopathic Constipation |
|
|
| Completed | 2 | 87 | Europe | prucalopride, Resolor, placebo | Movetis | Constipation | 03/99 | 03/99 | | |
NCT00627692: Evaluation of the Safety and Tolerability of Prucalopride in Constipated Elderly Subjects Living in a Nursing Facility |
|
|
| Completed | 2 | 100 | US | Prucalopride, Resolor, Placebo | Movetis | Constipation | 05/00 | 05/00 | | |
NCT00793247: Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP) |
|
|
| Completed | 2 | | Europe | PRU-PLA-PRU-PLA, PLA-PRU-PLA-PRU, PLA-PRU-PRU-PLA, PRU-PLA-PLA-PRU | Movetis | Chronic Intestinal Pseudo-Obstruction | | | | |
2011-000308-16: Prucalopride versus placebo in patients with significantly delayed gastric emptying of idiopathic and diabetic nature |
|
|
| Ongoing | 2 | 60 | Europe | Film-coated tablet, Resolor | UZ Leuven, Shire | Patients with delayed gastric emptying (t1/2 for solids ≥ 109 min) either from idiopathic or diabetic origin, delayed gastric emptying (when it takes ≥ 109 minutes before half of a standard solid meal has left the stomach) either from idiopathic or diabetic origin, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT02538367: Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation |
|
|
| Completed | 1/2 | 120 | RoW | YH12852 IR 0.05mg, YH12852 IR 0.1mg, YH12852 IR 0.3mg, YH12852 IR 0.5mg, YH12852 IR 1mg, YH12852 IR 2mg, YH12852 IR 3mg, YH12852 DR1 0.5mg, YH12852 DR1 1mg, YH12852 DR1 2mg, YH12852 DR1 4mg, YH12852 DR2 8mg, Prucalopride 2mg, Placebo | Yuhan Corporation | Functional Constipation | 09/16 | 09/16 | | |
